- Through existing relationships with leading hospital centres and research universities, including the Christie Hospital, the largest oncology centre in Europe, and the University of Manchester, Albert Labs will pursue the rapid commercial deployment of its natural, psilocybin-based prescription medication upon completion of clinical trials and receipt of regulatory approval.
- Using the real-world evidence clinical model, the company will accelerate clinical trials and allow it to reach regulatory approval much faster than traditional trials.
- Albert Labs has a proprietary and provisionally patented process for producing the active ingredient in its medicines that allows improved scale and standardization.
- A diverse team of doctors, scientists and managers, who together have brought more than 200 drugs to market, is leading the company toward receiving approval for its inaugural medicine and beyond.
- Albert Labs has signed a letter of intent with full-service contract-research organization NGENū to carry out the company's first in-human study of its primary drug target, KRN-101.
Cancer treatments have come a long way, but they have a major blind spot that needs to be addressed: mental health associated with the diagnosis. In 2020, there were 18 million new cancer cases globally, and that’s expected to climb to 27.5 million new cases annually by 2040. Cancer-related distress, including depression, anxiety, and existential crisis impacts 56 percent of cancer patients.
Despite this need, cancer-related distress often goes untreated due to contraindications with cancer treatments. These risks often result in oncologists being fearful to prescribe traditional first-line antidepressants, leaving cancer patients with only psychiatric counseling to treat their distress which has limited success in this patient cohort.
Facing a cancer diagnosis is difficult enough. Facing it without effective psychiatric support is even more challenging. Patients report feelings of helplessness and a hastened desire for death. Researchers are now exploring how natural psychedelic compounds can be transformed into practical mental health treatments for cancer patients. Psilocybin has already been shown to be effective in treating major depression. Will these bold new medications finally give patients relief?
Albert Labs (CSE:ABRT) is a Vancouver-based research and drug development company focused on improving patient access to innovative mental health medications. The company is presently developing a natural psilocybin-based medication for patients with cancer-related distress. With the intention of expanding its clinical development program to address other unmet mental health needs after initial success.